***Background.*** The polysaccharide capsule in *E. coli* is a major pathogenic factor. Loss of encapsulation results in complete attenuation in an otherwise lethal systemic murine infection model. We have previously identified a small molecule inhibitor of capsule biogenesis (designated DU011) and identified its target as MprA, a transcriptional repressor of multi-drug efflux pumps. Unlike other proposed MprA ligands such as salicylate and 2,4-dinitrophenol (DNP), DU011 does not alter *E. coli* antibiotic resistance and has significantly enhanced inhibition of capsule expression. We hypothesized that DU011 interacts uniquely in the MprA binding pocket relative to other ligands to produce a different phenotype and sought to define critical residues in the binding pocket to optimize inhibitor design.

***Methods.*** To identify mutations within MprA that confer resistance to DU011, a plasmid carrying *mprA* was randomly mutated in DNA repair deficient XL-Red cells. In a non-mutator strain of *E.coli,* plasmids were screened for DU011 and DNP resistance by using a capsule dependent phage assay. Individual clones were selected and the plasmids sequenced.

***Results.*** Mutant MprA clones were identified that conferred shared and specific resistance to DU011 and DNP. Mutations mapped to the predicted binding pocket as modeled *in* silico. Biophysical studies demonstrated altered and abrogated binding of DU011 and DNP in purified mutant MprA proteins.

***Conclusion.*** DNP and DU011 use different residues for binding to MprA, which may explain their differential effects on multi-drug efflux pump and capsule regulation. Molecules that target the amino acid residues that are part of the DU011 binding pocket would be good candidates as therapeutics that would inhibit a major pathogenic factor in *E .coli* while maintaining the repression of multi-drug efflux pumps and thereby eliminating a major mechanism of resistance to such molecules.
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